全文获取类型
收费全文 | 55950篇 |
免费 | 5110篇 |
国内免费 | 375篇 |
专业分类
耳鼻咽喉 | 163篇 |
儿科学 | 1496篇 |
妇产科学 | 2056篇 |
基础医学 | 3986篇 |
口腔科学 | 790篇 |
临床医学 | 4320篇 |
内科学 | 11827篇 |
皮肤病学 | 546篇 |
神经病学 | 4040篇 |
特种医学 | 840篇 |
外国民族医学 | 1篇 |
外科学 | 4955篇 |
综合类 | 1434篇 |
现状与发展 | 4篇 |
一般理论 | 7篇 |
预防医学 | 16504篇 |
眼科学 | 729篇 |
药学 | 2346篇 |
4篇 | |
中国医学 | 60篇 |
肿瘤学 | 5327篇 |
出版年
2024年 | 81篇 |
2023年 | 2562篇 |
2022年 | 3695篇 |
2021年 | 3839篇 |
2020年 | 4258篇 |
2019年 | 2805篇 |
2018年 | 2916篇 |
2017年 | 3285篇 |
2016年 | 3130篇 |
2015年 | 2949篇 |
2014年 | 4811篇 |
2013年 | 3597篇 |
2012年 | 2576篇 |
2011年 | 2376篇 |
2010年 | 2942篇 |
2009年 | 2622篇 |
2008年 | 1519篇 |
2007年 | 1519篇 |
2006年 | 1252篇 |
2005年 | 1065篇 |
2004年 | 847篇 |
2003年 | 817篇 |
2002年 | 775篇 |
2001年 | 749篇 |
2000年 | 657篇 |
1999年 | 641篇 |
1998年 | 408篇 |
1997年 | 372篇 |
1996年 | 328篇 |
1995年 | 292篇 |
1994年 | 204篇 |
1993年 | 167篇 |
1992年 | 251篇 |
1991年 | 231篇 |
1990年 | 201篇 |
1989年 | 165篇 |
1988年 | 129篇 |
1987年 | 44篇 |
1986年 | 17篇 |
1985年 | 28篇 |
1984年 | 38篇 |
1983年 | 29篇 |
1982年 | 20篇 |
1981年 | 21篇 |
1980年 | 26篇 |
1979年 | 16篇 |
1978年 | 16篇 |
1977年 | 14篇 |
1974年 | 15篇 |
1973年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
21.
22.
23.
24.
《Survey of ophthalmology》2022,67(4):1031-1047
Uveal coloboma is a condition defined by missing ocular tissues and is a significant cause of childhood blindness. It occurs from a failure of the optic fissure to close during embryonic development and may lead to missing parts of the iris, ciliary body, retina, choroid, and optic nerve. Because there is no treatment for coloboma, efforts have focused on prevention. While several genetic causes of coloboma have been identified, little definitive research exists regarding the environmental causes of this condition. We review the current literature on environmental factors associated with coloboma in an effort to guide future research and preventative counseling related to this condition. 相似文献
25.
《Journal of diabetes and its complications》2022,36(12):108340
Diabetes mellitus is the leading disorder and affects more than millions of people worldwide. Nowadays, the usage of herbal drugs is said to control adiposity and hyperglycemia. The current research investigated the anti-adiposity and antidiabetic activity of S. saman leaf extract and bioactive compounds. Therefore, the results lower the sugar absorption into the blood and reveal the extract's antidiabetic properties. STZ-induced diabetic rats, Samanea saman methanolic extract show improvement in the parameters like fasting blood glucose levels, body weight, other biochemical parameters supported by the histopathological analysis, and an increase in serum levels in the experimental groups. The antioxidant plays a vital role by increasing SOD and catalase activity levels and decreasing lipid peroxidation levels. The methanolic extract protects the tissue from oxidation stress, which is responsible for the glycemic properties. According to the findings, diabetic-treated rats had overnight blood glucose levels lower and near standard biochemical markers. Histopathology of the liver, pancreas, kidneys, and adipose tissues supported the pharmacological observations.Further, we screened and documented S. saman extract used for in vitro and in vivo methods. In terms of effectiveness, the crude extracts exhibit 0.8-fold GLUT4 down-regulation. Consequently, this result contributes to clinical trials and develops antidiabetic therapy as a substitute for synthetic pharmaceuticals. 相似文献
26.
27.
28.
29.
《The American journal of medicine》2022,135(7):879-888.e3
ObjectivesClinical trials have shown a beneficial effect from biological disease-modifying antirheumatic drugs (bDMARDs) on hand or axial bone loss in patients with rheumatoid arthritis; however, it is unclear if this translates to a reduced fracture risk. We investigated the effect of bDMARDs on osteoporotic fracture risk compared to no biological treatment in rheumatoid arthritis.MethodsA cohort of patients with rheumatoid arthritis aged 18+ from DANBIO was linked to population-based health registries in Denmark (2006-2016). Adopting a prevalent new-user design, we matched bDMARD users to bDMARD-naïve patients using time-conditional propensity scores. The risk of incident osteoporotic fractures (including hip, vertebrae, humerus, and forearm) was estimated among the matched patients by Cox proportional hazards models.ResultsOut of 24,678 patients with rheumatoid arthritis, 4265 bDMARD users were matched to the same number of bDMARD-naïve patients (mean age 56.2 years, 74% female). During follow-up, 229 osteoporotic fractures occurred among bDMARD users and 205 fractures among bDMARD-naïve patients (incidence rates 12.1 and 13.0 per 1000 person-years, respectively). The use of bDMARDs was not associated with a reduced risk of osteoporotic fractures among patients with rheumatoid arthritis (hazard ratio 0.97, 95% confidence interval 0.78-1.20), compared with no biological treatment. The risk estimates were similar for all osteoporotic fracture sites.ConclusionWe found no independent beneficial effect from using bDMARDs on reducing the risk of osteoporotic fractures in patients with rheumatoid arthritis. 相似文献
30.